HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market – Forecast To 2023

Publishing Date :	November, 2017
Report Code :	HCPH 0107
Price:	Single license $4,950 Site license $6,750 Global license $9,000

Note: The report would be dispatched after confirmation of payment

The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) ≤ 10µg/m³. The HPAPI global market is progressively increasing in terms of revenue and the rise in demand for outsourcing these intermediates, manufacturing is driven by expansion of oncology sector, which is the fastest among overall pharmaceutical sector.

The global HPAPI market is poised to grow at a high single digit CAGR to reach $27,293.4 million by 2023. HPAPI market is mainly classified by customer base, by business type, by molecule type and Applications. The global HPAPI market is broadly classified as Innovative HPAPI and Generic HPAPI based on customer base. Based on business type, the market is classified into Captive HPAPI & Merchant HPAPI. HPAPI market is segmented on the basis of molecule type as Synthetic HPAPI and Biotech HPAPI. HPAPI market application segment is classified into Oncology, Cardiovascular, Central Nervous System, Hormonal, Glaucoma, Infectious, metabolic, Inflammation and other therapeutic applications.

Among Innovative & generic HPAPI, Innovative HPAPI occupies the major share during 2016 and generic HPAPIs expected to grow at a highest CAGR from 2016 to 2023. Among business type, Captive HPAPI occupies the major share during 2016 and Merchant HPAPI is expected to grow at a highest CAGR from 2016 to 2023. Among molecule type, Synthetic HPAPI occupied the major share during 2016 and is expected to grow at high single digit CAGR from 2016 to 2023 to reach $17,434.4 million by 2023. Among Application segment, Oncology commanded the larger revenue in 2016 and is expected to grow at highest CAGR from 2016 to 2023.

Increasing incidence of chronic and age-related diseases, rapid growth in oncology market, growing demand for Antibody Drug Conjugates (ADC), technological advancements in HPAPI market, growing CMOs are some of the factors which are driving the market. Requirement of large investments, stringent safety and handling specifications associated with production of HPAPI, stringent regulations are the factors hindering the market.

North America accounted for the highest market share in 2016 and followed by Europe. However, Asian countries especially China and India are the fastest growing regions with its growing demand for HPAPIs. Asia-Pacific is projected to grow with a highest CAGR from 2016 to 2023.

Major players in HPAPI market include Alkermes PLC (Ireland), Cambrex Corporation (U.S.),Dishman group (India), Dr. Reddy’s Laboratories (India), Lonza Group (Switzerland), Novasep (U.S.), Patheon N.V.( Netherland)(ThermoFisher Scientific), Pfizer (U.S.), Merck KGaA (Germany) and Teva Pharmaceutical Industries (Israel).

The report provides an in-depth market analysis of the above mentioned segments across the following regions:

North America
Europe
Asia-Pacific
Rest of the World

1 EXECUTIVE SUMMARY
2 INTRODUCTION

2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY

2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
2.5.8 KEY CHARECTERISTICS OF HPAPI MANUFACTURING

3 MARKET ANALYSIS

3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET

3.3.1 DRIVERS AND OPPORTUNITIES

3.3.1.1 INCREASING INCIDENCE OF CHRONIC AND AGE RELATED DISEASES
3.3.1.2 RAPID GROWTH IN ONCOLOGY MARKET
3.3.1.3 GROWING DEMAND FOR ANTIBODY DRUG CONJUGATES (ADCS)
3.3.1.4 TECHNOLOGICAL ADVANCEMENTS IN HPAPI MARKET
3.3.1.5 GROWING CMOS (CONTRACT MANUFACTURING ORGANIZATIONS) MARKET

3.3.2 RESTRAINTS AND THREATS

3.3.2.1 REQUIREMENT OF LARGE INVESTMENT
3.3.2.2 STRINGENT SAFETY AND HANDLING SPECIFICATIONS ASSOCIATED WITH THE PRODUCTION OF HPAPI
3.3.2.3 STRINGENT REGULATIONS
3.3.2.4 ALTERNATIVE THERAPIES TO CURE THE CANCER

3.4 PORTER’S FIVE FORCE ANALYSIS

3.4.1 THREAT OF NEW ENTRANTS
3.4.2 THREAT OF SUBSTITUTES
3.4.3 RIVALRY AMONG EXISTING COMPETITORS
3.4.4 BARGAINING POWER OF BUYERS
3.4.5 BARGAINING POWER OF SUPPLIERS

3.5 REGULATORY AFFAIRS

3.5.1 U.S.
3.5.2 EUROPE
3.5.3 ASIA PACIFIC
3.5.4 REST OF THE WORLD

3.6 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.7 SUPPLY CHAIN ANALYSIS
3.8 SELECTED TOP SELLING HPAPI
3.9 RECENT HPAPI INVESTMENTS

4 HPAPI GLOBAL MARKET, BY CUSTOMER BASE

4.1 INTRODUCTION
4.2 INNOVATIVE HPAPI
4.3 GENERIC HPAPI

5 HPAPI GLOBAL MARKET, BY BUSINESS TYPE

5.1 INTRODUCTION
5.2 CAPTIVE HPAPAI
5.3 MERCHANT HPAPI

6 HPAPI GLOBAL MARKET, BY MOLECULE TYPE

6.1 INTRODUCTION
6.2 SYNTHETIC HPAPIS
6.3 BIOTECH HPAPIS

7 HPAPI GLOBAL MARKET, BY APPLICATIONS

7.1 INTRODUCTION
7.2 CENTRAL NERVOUS SYSTEM DISORDERS
7.3 ONCOLOGY
7.4 HORMONAL DISORDERS
7.5 GLAUCOMA
7.6 INFECTIOUS DISEASES
7.7 METABOLIC DISORDERS
7.8 CARDIOVASCULAR
7.9 INFLAMMATION
7.10 OTHER THERAPEUTIC APPLICATIONS

8 REGIONAL MARKET ANALYSIS

8.1 INTRODUCTION
8.2 NORTH AMERICA

8.2.1 U.S.
8.2.2 OTHERS

8.3 EUROPE

8.3.1 SWITZERLAND
8.3.2 GERMANY
8.3.3 U.K.
8.3.4 OTHERS

8.4 ASIA PACIFIC

8.4.1 INDIA
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 OTHERS

8.5 REST OF THE WORLD (ROW)

8.5.1 BRAZIL
8.5.2 REST OF LATIN AMERICA
8.5.3 MIDDLE EAST & OTHERS

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION

10 MAJOR COMPANIES

10.1 ALKERMES PLC

10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 SERVICE PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS

10.2 CAMBREX CORPORATION

10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 SERVICE PORTFOILIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS

10.3 DISHMAN GROUP

10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 SERVICE PORTFOILIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS

10.4 DR. REDDY’S LABORATORIES

10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 SERVICE PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY
10.4.6 SWOT ANALYSIS

10.5 LONZA GROUP

10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 SERVICE PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS

10.6 NOVASEP

10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 SERVICE PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS

10.7 PATHEON N.V.(THERMOFISHER SCIENTIFIC)

10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 SERVICE PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STARTEGY
10.7.6 SWOT ANALYSIS

10.8 PFIZER INC.

10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 SERVICE PORTFOLIO
10.8.5 KEY DEVELOPMENTS
10.8.6 BUSINESS STRATEGY
10.8.7 SWOT ANALYSIS

10.9 MERCK KGAA

10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS

10.10 TEVA PHARMACEUTICAL INDUSTRIES

10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 SERVICE PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS

LIST OF TABLES

TABLE 1 HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 2 HPAPI GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2015-2023) ($MN)
TABLE 3 INNOVATIVE HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 4 GENERIC HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 5 HPAPI GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2015-2023) ($MN)
TABLE 6 CAPTIVE HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 7 MERCHANT HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 8 HPAPI GLOBAL MARKET REVENUE, BY MOLECULE TYPE (2015-2023) ($MN)
TABLE 9 SYNTHETIC HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 10 BIOTECH HPAPI GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 11 HPAPI GLOBAL MARKET REVENUE, BY APPLICATIONS, (2015-2023) ($MN)
TABLE 12 CENTRAL NERVOUS SYSTEMS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
TABLE 13 ONCOLOGY HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) $MN)
TABLE 14 HORMONAL DISORDERS HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
TABLE 15 GLAUCOMA HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
TABLE 16 INFECTIOUS DISEASES HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
TABLE 17 METABOLIC DISORDERS HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
TABLE 18 CARDIOVASCULAR HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
TABLE 19 INFLAMMATION HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
TABLE 20 OTHER APPLICATIONS HPAPI GLOBAL MARKET REVENUE,BY REGION, (2015-2023) ($MN)
TABLE 21 NORTH AMERICAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
TABLE 22 NORTH AMERICAN HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
TABLE 23 NORTH AMERICAN HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
TABLE 24 NORTH AMERICAN HPAPI MARKET REVENUE,BY APPLICATIONS , (2015-2023) ($MN)
TABLE 25 EUROPEAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
TABLE 26 EUROPEAN HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
TABLE 27 EUROPEAN HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
TABLE 28 EUROPEAN HPAPI MARKET REVENUE,BY APPLICATIONS, (2015-2023) ($MN)
TABLE 29 ASIA PACIFIC HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
TABLE 30 ASIA PACIFIC HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
TABLE 31 ASIA PACIFIC HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
TABLE 32 ASIA PACIFIC HPAPI MARKET REVENUE,BY APPLICATIONS, (2015-2023) ($MN)
TABLE 33 ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2015-2023) ($MN)
TABLE 34 ROW HPAPI MARKET REVENUE, BY BUSINESS TYPE, (2015-2023) ($MN)
TABLE 35 ROW HPAPI MARKET REVENUE,BY MOLECULE TYPE, (2015-2023) ($MN)
TABLE 36 ROW HPAPI MARKET REVENUE,BY APPLICATIONS (2015-2023) ($MN)
TABLE 37 EXPANSIONS, AGREEMENTS, ACQUISTIONS, APPROVALSAND OTHER DEVELOPMENTS (2015-2017)
TABLE 38 ALKERMES PLC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 39 ALKERMES PLC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
TABLE 40 ALKERMES PLC: TOTAL REVENUE, BY SUB-SEGMENTS, (2015-2017) ($MN)
TABLE 41 ALKERMES PLC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
TABLE 42 CAMBREX CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 43 CAMBREX CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
TABLE 44 DISHMAN GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 45 DISHMAN GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 46 DR. REDDY’S LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 47 DR. REDDY’S LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 48 DR. REDDY’S LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 49 LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
TABLE 50 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
TABLE 51 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
TABLE 52 PATHEON N.V.: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
TABLE 53 PATHEON N.V.: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
TABLE 54 PATHEON N.V.: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
TABLE 55 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 56 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
TABLE 57 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
TABLE 58 MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 59 MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
TABLE 60 MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
TABLE 61 TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 62 TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
TABLE 63 TEVA PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)

LIST OF FIGURES

FIGURE 1 HPAPI GLOBAL MARKET SHARE AND REVENUE, BY REGION (2015-2023)
FIGURE 2 RESEARCH METHODOLOGY: HPAPI GLOBAL MARKET
FIGURE 3 HPAPI GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 HPAPI GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 HPAPI GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 HPAPI GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 HPAPI GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 9 HPAPI GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS 2016 (%)
FIGURE 10 HPAPI MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 11 HPAPI GLOBAL MARKET SHARE, BY CUSTOMER BASE (2016 V/S 2023) (%)
FIGURE 12 HPAPI GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2016 V/S 2023) ($ MN)
FIGURE 13 HPAPI GLOBAL MARKET REVENUE, BY MOLECULE TYPE (2016 V/S 2023) ($ MN)
FIGURE 14 HPAPI GLOBAL MARKET SHARE, BY APPLICATIONS (2016) (%)
FIGURE 15 HPAPI GLOBAL MARKET SHARE AND REVENUE, BY REGION (2016-2023) ($MN)
FIGURE 16 NORTH AMERICAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 17 NORTH AMERICAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 18 UNITED STATES HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 19 UNITED STATES HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 20 OTHER NORTH AMERICAN REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 21 OTHER NORTH AMERICAN REGIONS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 22 EUROPEAN HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 23 EUROPEAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) ($MN)
FIGURE 24 SWITZERLAND HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 25 SWITZERLAND HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 26 GERMANY HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 27 GERMANY HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 28 U.K. HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 29 U.K. HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 30 OTHER EUROPEAN REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 31 OTHER EUROPEAN REGIONS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 32 ASIA PACIFIC HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 33 ASIA PACIFIC HPAPI MARKET SHARE,BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 34 INDIA HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 35 INDIA HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 36 CHINA HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 37 CHINA HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 38 JAPAN HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 39 JAPAN HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 40 OTHER ASIA PACIFIC REGIONS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) (%)
FIGURE 41 OTHER ASIA PACIFIC REGIONS HPAPI SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 42 ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE,BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 43 ROW HPAPI MARKET SHARE BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 44 BRAZIL HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 45 BRAZIL HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 46 REST OF LATIN AMERICA HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 47 REST OF LATIN AMERICA HPAPI MARKET REVENUE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 48 MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BY CUSTOMER BASE, BUSINESS TYPE & MOLECULE TYPE (2016 V/S 2023) ($MN)
FIGURE 49 MIDDLE EAST & OTHERS HPAPI MARKET SHARE, BY APPLICATIONS (2016 V/S 2023) (%)
FIGURE 50 KEY GROWTH STRATEGIES, (2015 – 2017)
FIGURE 51 SWOT: ALKERMES PLC
FIGURE 52 SWOT: CAMBREX CORPORATION
FIGURE 53 SWOT: DISHMAN GROUP
FIGURE 54 SWOT: DR. REDDY’S LABORATORIES
FIGURE 55 SWOT: LONZA GROUP
FIGURE 56 SWOT: NOVASEP
FIGURE 57 SWOT: PATHEON N.V.
FIGURE 58 SWOT: PFIZER INC.
FIGURE 59 SWOT: MERCK KGAA
FIGURE 60 SWOT: TEVA PHARMACEUTICAL INDUSTRIES

LIST OF COMPANIES MENTIONED IN THE REPORT

1 AENOVA GROUP GMBH
2 ALKERMES PLC
3 ALMAC GROUP
4 ABBOTT LABORATORIES
5 ABBVIE CONTRACT MANUFACTURING
6 ADC BIOTECHNOLOGY
7 ADC THERAPEUTICS
8 AGNO PHARMA
9 AJINOMOTO (ALTHEA INC.)
10 ALCAMI CORPORATION
11 AMPAC FINE CHEMICALS
12 AMRI GLOBAL
13 ANVI PHARMA
14 ASTRAZENECA(SPIROGEN)
15 ASYMCHEM LABORATORIES
16 AVANTHERA S.A.
17 AVARA PHARMACEUTICAL SERVICES
18 AXCELLERATE PHARMA SERVICES
19 BACHEM
20 BAXTER INTERNATIONAL
21 BAYER
22 BIOCON LIMITED
23 BIOPHARMA TECHNOLOGY
24 BIOPHORE INDIA PHARMACEUTICALS PVT. LTD
25 BIOVECTRA
26 BIOTECHNIQUE
27 BOEHRINGER INGELHEIM
28 BRISTOL-MYERS SQUIBB
29 BRYLLAN LLC
30 BUCHIGLAS-USA CORP.
31 CAMBREX CORPORATION
32 CATALENT PHARMA SOLUTIONS INC
33 CELGENE BIOTECHNOLOGY
34 CERBIOS PHARMA SA
35 CHEMCON
36 CHEMIGRAN PTE LTD.
37 CIPLA
38 CONSORT MEDICAL
39 CUSTOM PROCESSING SERVICES INC
40 DALTON PHARMA SERVICES
41 DEC-USA INC.
42 DISHMAN GROUP
43 DOTTIKON EXCLUSIVE SYNTHESIS
44 DR. REDDY'S LABORATORIES
45 EMCURE PHARMACEUTICALS
46 ESTEVE QUIMICA
47 EUROFINS SCIENTIFIC
48 EUTICALS
49 EVONIK INDUSTRIES
50 EVOTEC A.G.
51 FAREVA
52 FARHISPANIA GROUP
53 FERMION
54 FERRO CORPORATION
55 FORMOSA LABORATORIES INC.
56 FRESENIUS KABI
57 GRANUELS
58 GP PHARM
59 HELSIN ADVANCED SYNTHESIS.
60 HERAEUS
61 HIKAL LIMITED
62 HIKMA PHARMACEUTICALS
63 HOVIONE
64 ICROM S.P.A
65 IDIFARMA PHARMACEUTICAL DEVELOPMENT S.L.
66 INTAS BIOPHARMACEUTICALS
67 INTERNATIONAL CHEMICAL INVESTORS S. E
68 JOHNSON MATTHEY
69 KYONGBO PHARMACEUTICAL CO. LTD
70 LAURUS SYNTHESIS INC
71 LIPOCINE
72 LONZA GROUP
73 LUPIN LIMITED
74 MAYNE PHARMA (LIBERTAS PHARMA INC)
75 MEDICHEM
76 MERCK KGAA
77 MERSANA THERAPEUTICS INC.
78 MINAKEM HIGH POTENT
79 MITSUBISHI TANABE PHARMA CORP.
80 NATCO PHARMA
81 NEULAND HEALTH SCIENCES PRIVATE LIMITED
82 NOVARTIS
83 NOVASEP HOLDING SAS
84 OLON S.P.A.
85 OPKO HEALTH
86 OSO BIOPHARMACEUTICALS MANUFACTURING LLC
87 PCAS
88 PFANSTIEHL
89 PFIZER
90 PIERRE FABRE
91 PIRAMAL PHARMA SOLUTION
92 POWDER SYSTEMS LIMITED
93 PROCOS S.P.A
94 PROJECT PHARMACEUTICS
95 QS PHARMA LLC
96 REGIS TECHNOLOGIES INC.
97 R-PHARM GERMANY GMBH.
98 SCINOPHARM TAIWAN LIMITED
99 SEATTLE GENETICS INC.
100 SEIGRIED HOLDING
101 SERVIER CDMO
102 SHILPA MEDICARE
103 STASON PHARMACEUTICALS
104 STRIDES ARCOLABS
105 SUNDIA MEDITECH
106 SYMBIOSIS PHARMACEUTICAL SERVICES
107 SYNTAGON AB
108 SYNTHON BIOPHARMACEUTICALS
109 TEVA PHARMACEUTICAL INDUSTRIES
110 THERMOFISHER SCIENTIFIC (PATHEON N.V.)
111 UMAN PHARMA
112 UMICORE N.V.
113 VION PHARMACEUTICALS, INC
114 VXP PHARMA SERVICES
115 WUXI PHARMATEC
116 YPROTECH LIMITED

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market – Forecast To 2023

LIST OF TABLES

LIST OF FIGURES

LIST OF COMPANIES MENTIONED IN THE REPORT

IQ4I HEALTHCARE REPORTS

about IQ4I

Get in Touch

IQ4I Quality Accredit Certificate

Subscribe to Newsletter

Pharmaceuticals

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market – Forecast To 2023

HPAPI (High Potency Active Pharmaceutical Ingredients) Global Market – Forecast To 2023

LIST OF TABLES

LIST OF FIGURES

LIST OF COMPANIES MENTIONED IN THE REPORT

IQ4I HEALTHCARE REPORTS